Business
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass., May 07, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development with Biogen (Nasdaq: BIIB) as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the first quarter ended March 31, 2026, and announced new 4-year longitudinal data
About this update from Stoke Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":223,"url":"https://media.zenfs.com/en/business-wire.com/813cbacc05bcd13c6e87b572b69cfc18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Kor9orhIcwv4uSTt7izm0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0Ng--/https://media.zenfs.com/en/business-wire.com/813cbacc05bcd13c6e87b572b69cfc18","width":480,"height":223},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/.PjljDmTw5ah1siwHwyEkw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI5Nw--/https://media.zenfs.com/en/business-wire.com/813cbacc05bcd13c6e87b572b69cfc18","width":480,"height":223}},"lazy":false},{"type":"text","content":"– New 4-year longitudinal data from the Phase 1/2a open-label extension (OLE) studies provide additional support for the disease-modifying potential of zorevunersen, an investigational medicine for the treatment of Dravet syndrome –","length":232,"tagName":"p","attribs":{}},{"type":"text","content":"– Statistically significant improvements in cognition and behavior demonstrated at 1, 2, 3 and 4 years of treatment compared to OLE baseline, in addition to continued durability in seizure reductions –","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"– Zorevunersen generally well tolerated, with some patients treated for more than 5 years –","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"– Enrollment of approximately 150 patients into the Phase 3 EMPEROR study expected to complete in June 2026 to support a data readout in mid-2027; these data are anticipated to complete the rolling U.S. NDA submission planned to initiate in first quarter 2027 –","length":261,"tagName":"p","attribs":{}},{"type":"text","content":"– As of March 31, 2026, the Company had $411.0 million in cash, cash equivalents and marketable securities expected to fund operations into 2028, including $80.7 million raised through selective ATM sales in first quarter 2026 –","length":228,"tagName":"p","attribs":{}},{"type":"text","content":"– Webcast and conference call for analysts and investors at 4:30PM Eastern Time today –","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"BEDFORD, Mass., May 07, 2026--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restorin...